CSNK1A1 and infection: While the Quintavalle et al., study utilizes non-FDA approved casein kinase inhibitors, FDA approved alternatives, such as pyrvinium, have been shown to potently inhibit casein kinase 1 alpha (CK1α) and could be investigated in the context of flaviviral infection [81].